European Medicines Agency and MHRA validate applications to expand licence of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in cystic fibrosis

Approval is sought for use in combination with ivacaftor in patients age ≥6 years who have ≥1 F508del mutation in CFTR gene. If approved, this will extend indication for the triple combination therapy to children ages 6 through to 11 years

Source:

PharmaTimes